A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

NCT03897868 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: HCP1803
DRUG: Amlodipine
DRUG: Losartan
DRUG: Placebo

Sponsor

Hanmi Pharmaceutical Company Limited